| 1 |
34081952 | Metabolic remodeling precedes mTORC1-mediated cardiac hypertrophy. | 2021 Sep |
2 |
| 2 |
34253722 | TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism. | 2021 Jul 12 |
1 |
| 3 |
32191726 | Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure. | 2020 |
1 |
| 4 |
32375878 | Tsc1 haploinsufficiency in Nkx2.1 cells upregulates hippocampal interneuron mTORC1 activity, impairs pyramidal cell synaptic inhibition, and alters contextual fear discrimination and spatial working memory in mice. | 2020 May 6 |
1 |
| 5 |
32588887 | Ornithine decarboxylase, the rate-limiting enzyme of polyamine synthesis, modifies brain pathology in a mouse model of tuberous sclerosis complex. | 2020 Aug 11 |
1 |
| 6 |
32781001 | Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout. | 2020 Dec |
1 |
| 7 |
33159078 | mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline. | 2020 Nov 6 |
2 |
| 8 |
30816188 | Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells. | 2019 Feb 28 |
1 |
| 9 |
30816216 | Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice. | 2019 Feb 28 |
1 |
| 10 |
31078684 | Cerebral aquaporin-4 expression is independent of seizures in tuberous sclerosis complex. | 2019 Sep |
1 |
| 11 |
31182914 | Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer. | 2019 |
1 |
| 12 |
31207499 | Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/- Mice. | 2019 Aug |
1 |
| 13 |
29396625 | TSC1 and TSC2 regulate cilia length and canonical Hedgehog signaling via different mechanisms. | 2018 Jul |
1 |
| 14 |
28808237 | Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment. | 2017 Aug 14 |
1 |
| 15 |
28972182 | Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors. | 2017 Dec 15 |
2 |
| 16 |
26854565 | Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. | 2016 Mar |
1 |
| 17 |
27278252 | Tuberin regulates reactive oxygen species in renal proximal cells, kidney from rodents, and kidney from patients with tuberous sclerosis complex. | 2016 Aug |
1 |
| 18 |
24632604 | Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. | 2015 Feb 12 |
2 |
| 19 |
24931163 | mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. | 2015 Apr 23 |
1 |
| 20 |
25613864 | Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. | 2015 Feb 20 |
2 |
| 21 |
23081885 | Fetal brain mTOR signaling activation in tuberous sclerosis complex. | 2014 Feb |
2 |
| 22 |
25155956 | Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. | 2014 Sep 3 |
1 |
| 23 |
21802234 | T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. | 2012 Sep |
2 |
| 24 |
23035046 | Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). | 2012 Oct 3 |
1 |
| 25 |
21062901 | Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. | 2011 Feb 1 |
1 |
| 26 |
20146790 | Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. | 2010 Feb 10 |
3 |
| 27 |
20159776 | Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. | 2010 May 15 |
1 |
| 28 |
20656472 | Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition. | 2010 Oct |
4 |
| 29 |
19143643 | Therapeutic targeting of mTOR in tuberous sclerosis. | 2009 Feb |
1 |
| 30 |
19368729 | Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. | 2009 Apr 15 |
2 |
| 31 |
19420259 | Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. | 2009 May 6 |
1 |
| 32 |
19539245 | Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. | 2009 Jun |
2 |
| 33 |
18587048 | Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. | 2008 Jul 8 |
1 |
| 34 |
18664580 | mTORC1 promotes survival through translational control of Mcl-1. | 2008 Aug 5 |
1 |
| 35 |
17290308 | PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. | 2007 Mar |
1 |
| 36 |
17986349 | Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. | 2007 Nov 6 |
1 |
| 37 |
15150095 | Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. | 2004 May 15 |
1 |
| 38 |
14561707 | Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. | 2003 Oct |
2 |